Skip to main content
SP5007,730.99+0.72%DOW53,569.44+0.20%NASDAQ26,541.35+1.57%BTC$80,260.00+1.84%ETH$2,508.78+0.33%GOLD$4,654.80-0.20%OIL$83.54+0.01%
Smart Investors Daily
Sign InSign Up Free
OP

OTC · OPGN

OpGen, Inc.

Healthcare · Medical - Diagnostics & Research

$23.91

Up+$9.75 (+68.86%)

Updated Aug 27, 2026, 9:57 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
101.62M
P/E ratio
14.85
Dividend yield
0.00%
52-week range
— – —
Volume
1.28K
Avg. volume
3.65K

Price performance

OPGN price history

1M range · 0 trading sessions · Daily adjusted prices

OPGN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest OPGN news

The latest Smart Investors Daily articles mentioning OPGN.

Stock researchCompany · Overview

OPGN research

Overview

Company profile and research snapshot.

Company profile

OPGEN INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$0.67
Implied upside
—
Analysts
—
OPGN recent ratings
DateFirmRatingTarget
Aug 14, 2023HC Wainwright & Co.Neutral—
Jul 20, 2023HC Wainwright & Co.Buy—
Jun 26, 2023HC Wainwright & Co.Buy—
Jun 21, 2023HC Wainwright & Co.Buy—
May 16, 2023HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · May 24, 2024

OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), which serves as an additional basis for delisting the Company’s securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company’s securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”).

GlobeNewswire Inc. · May 16, 2024

OpGen Announced 1-for-10 Reverse Stock Split

ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company’s board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company’s existing trading symbol “OPGN.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 68373L505.

GlobeNewswire Inc. · Apr 29, 2024

OpGen Provides Update on Business Operations and Strategic Opportunities

ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singaporean family office for $218,000. The transaction follows Camtech’s prior acquisition of all of Curetis GmhH’s (“Curetis”), the Company’s subsidiary, Unyvero assets, rights and businesses, as part of Curetis’ insolvency proceedings.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By